Another element worth mentioning about their FY 24 results : they were able to largely improve their EBITDA margin*, despite a sales decrease and an increase of 13 % for their staff costs (excluding staff cost included in their construction costs).
The only logical explanation for me is that the company continued to have a significant increase of its number of employees (+ 11.5 % in FY 24) because it expects an increase for its revenues going forward.
Employee costs/revenue was 4.8 % in FY 24 vs 3.9 % in FY 19 and 3.6 % in FY 20.
So, even if there is no further improvement for the gross margin, we could see an increase for EBITDA margin led by productivity (probably scenario : limited increase in the number of employees, with increase of revenues in FY 25 and FY 26).
If the company can return to its pre-covid level of employee cost/revenue of 3.75 %, it can increase its EBITDA margin by around 100 bp**, reaching an EBITDA margin of 4.1 %.
Reminder : Shape reached a peak EBITDA margin of 4.5 % in FY 19 (3.9 % in FY 20).
* only due to the large improvement of the gross margin.
** probably not in 1 year, but more on a period of 2 to 3 years.
- Forums
- ASX - By Stock
- SHA
- Ann: FY24 Results Announcement
Ann: FY24 Results Announcement, page-6
Featured News
Add SHA (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.77 |
Change
0.050(1.84%) |
Mkt cap ! $231.2M |
Open | High | Low | Value | Volume |
$2.72 | $2.78 | $2.72 | $3.786K | 1.369K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 9343 | $2.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.78 | 1570 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 9343 | 2.720 |
3 | 2629 | 2.700 |
1 | 3000 | 2.690 |
1 | 4400 | 2.680 |
3 | 9204 | 2.650 |
Price($) | Vol. | No. |
---|---|---|
2.780 | 1570 | 2 |
2.790 | 314 | 1 |
2.800 | 2000 | 1 |
2.810 | 3401 | 1 |
2.820 | 3000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
SHA (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online